RAF1 and endometrioid stromal sarcoma: These advances also identify the RAF/MEK/MAPK and Hippo pathways, and CDK4/6, as rational targets for evaluation of therapeutic strategies in HG-ESS with YWHAE-NUTM2 fusions.